JP2015057436A5 - - Google Patents

Download PDF

Info

Publication number
JP2015057436A5
JP2015057436A5 JP2014254924A JP2014254924A JP2015057436A5 JP 2015057436 A5 JP2015057436 A5 JP 2015057436A5 JP 2014254924 A JP2014254924 A JP 2014254924A JP 2014254924 A JP2014254924 A JP 2014254924A JP 2015057436 A5 JP2015057436 A5 JP 2015057436A5
Authority
JP
Japan
Prior art keywords
composition
patient
amino
aica riboside
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014254924A
Other languages
English (en)
Japanese (ja)
Other versions
JP6122417B2 (ja
JP2015057436A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015057436A publication Critical patent/JP2015057436A/ja
Publication of JP2015057436A5 publication Critical patent/JP2015057436A5/ja
Application granted granted Critical
Publication of JP6122417B2 publication Critical patent/JP6122417B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2014254924A 2005-03-28 2014-12-17 患者における副作用を予防または減少するための方法、組成物および処方物 Expired - Lifetime JP6122417B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66607105P 2005-03-28 2005-03-28
US60/666,071 2005-03-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012227809A Division JP2013010794A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016252553A Division JP2017057222A (ja) 2005-03-28 2016-12-27 患者における副作用を予防または減少するための方法、組成物および処方物

Publications (3)

Publication Number Publication Date
JP2015057436A JP2015057436A (ja) 2015-03-26
JP2015057436A5 true JP2015057436A5 (enExample) 2015-07-02
JP6122417B2 JP6122417B2 (ja) 2017-04-26

Family

ID=37054068

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2008504297A Pending JP2008534601A (ja) 2005-03-28 2006-03-28 患者における副作用を予防または減少するための方法、組成物および処方物
JP2012227809A Pending JP2013010794A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物
JP2012227810A Pending JP2013010795A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物
JP2014254924A Expired - Lifetime JP6122417B2 (ja) 2005-03-28 2014-12-17 患者における副作用を予防または減少するための方法、組成物および処方物
JP2016252553A Withdrawn JP2017057222A (ja) 2005-03-28 2016-12-27 患者における副作用を予防または減少するための方法、組成物および処方物
JP2019052531A Expired - Lifetime JP7093739B2 (ja) 2005-03-28 2019-03-20 患者における副作用を予防または減少するための方法、組成物および処方物
JP2020110456A Pending JP2020152737A (ja) 2005-03-28 2020-06-26 患者における副作用を予防または減少するための方法、組成物および処方物
JP2022075916A Withdrawn JP2022093641A (ja) 2005-03-28 2022-05-02 患者における副作用を予防または減少するための方法、組成物および処方物
JP2025031494A Pending JP2025084893A (ja) 2005-03-28 2025-02-28 患者における副作用を予防または減少するための方法、組成物および処方物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2008504297A Pending JP2008534601A (ja) 2005-03-28 2006-03-28 患者における副作用を予防または減少するための方法、組成物および処方物
JP2012227809A Pending JP2013010794A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物
JP2012227810A Pending JP2013010795A (ja) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2016252553A Withdrawn JP2017057222A (ja) 2005-03-28 2016-12-27 患者における副作用を予防または減少するための方法、組成物および処方物
JP2019052531A Expired - Lifetime JP7093739B2 (ja) 2005-03-28 2019-03-20 患者における副作用を予防または減少するための方法、組成物および処方物
JP2020110456A Pending JP2020152737A (ja) 2005-03-28 2020-06-26 患者における副作用を予防または減少するための方法、組成物および処方物
JP2022075916A Withdrawn JP2022093641A (ja) 2005-03-28 2022-05-02 患者における副作用を予防または減少するための方法、組成物および処方物
JP2025031494A Pending JP2025084893A (ja) 2005-03-28 2025-02-28 患者における副作用を予防または減少するための方法、組成物および処方物

Country Status (14)

Country Link
US (3) US8993527B2 (enExample)
EP (3) EP2594273A1 (enExample)
JP (9) JP2008534601A (enExample)
KR (1) KR20070121026A (enExample)
CN (1) CN101184495B (enExample)
AU (1) AU2006230242B2 (enExample)
BR (1) BRPI0608654C1 (enExample)
CA (1) CA2602291C (enExample)
MX (1) MX2007012045A (enExample)
NO (1) NO342207B1 (enExample)
NZ (1) NZ561649A (enExample)
SG (3) SG194352A1 (enExample)
WO (1) WO2006105167A2 (enExample)
ZA (1) ZA200708277B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006230242B2 (en) 2005-03-28 2013-05-30 Pericor Therapeutics, Inc. Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
DE102008007216A1 (de) 2007-05-29 2008-12-11 Samsung Electro - Mechanics Co., Ltd., Suwon Gedruckte Leiterplatte und Herstellungsverfahren derselben
EP2349284B1 (en) * 2008-10-03 2016-11-23 Pericor Therapeutics, Inc. Treatment of acute decompensated heart failure
EP2512489A4 (en) * 2009-12-15 2014-04-02 Merck Sharp & Dohme FORMULATIONS FROM ACADESIN
US8489182B2 (en) 2011-10-18 2013-07-16 General Electric Company System and method of quality analysis in acquisition of ambulatory electrocardiography device data
US11160879B2 (en) 2014-01-15 2021-11-02 Masamichi Yamamoto Transgenic animal for visualization of ATP and use thereof
EP3107548B8 (en) 2014-02-20 2022-07-20 Otitopic Inc. Dry powder formulations for inhalation
CN104140438B (zh) * 2014-06-11 2017-01-18 苏州景泓生物技术有限公司 5‑氨基‑4‑氨甲酰咪唑核苷碳环类似物的合成方法
CA2991760C (en) 2014-07-31 2025-05-06 Aspeya US Inc. DRY INHALATION POWDER FORMULATIONS
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
WO2018092911A1 (ja) * 2016-11-21 2018-05-24 株式会社スタージェン 細胞内ａｔｐ増強剤
JP6937134B2 (ja) 2016-11-21 2021-09-22 株式会社スタージェン 細胞内ａｔｐ増強剤
WO2019039438A1 (ja) * 2017-08-21 2019-02-28 国立大学法人三重大学 非ヒト哺乳類の脳梗塞モデルによる観察方法及び非ヒト哺乳類の脳梗塞モデルによる観察装置
AU2018336787B2 (en) 2017-09-19 2024-05-30 Corflow Therapeutics Ag Intracoronary characterization of microvascular obstruction (MVO) and myocardial infarction
EP4040991A4 (en) * 2019-10-09 2024-01-24 Mayo Foundation for Medical Education and Research TREATMENT OF GASTROINTESTINAL DISORDERS
EP3866176A1 (en) * 2020-02-17 2021-08-18 Siemens Healthcare GmbH Machine-based risk prediction for peri-procedural myocardial infarction or complication from medical data
EP4792852A2 (en) 2020-05-22 2026-08-19 CorFlow Therapeutics AG Controlled flow infusion microvascular dysfunction diagnostic and therapy
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
US20260102457A1 (en) * 2022-09-26 2026-04-16 The Penn State Research Foundation Anticoagulant-peptide nanogranules for thrombosis-actuated anticoagulation
KR20250161553A (ko) * 2023-03-13 2025-11-17 울트라사운드 에이아이, 인코포레이티드 의료 이미징을 통한 포괄적인 의료 진단, 예후, 및 치료 최적화를 위한 인공 지능 시스템

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1645976A1 (de) 1966-06-18 1971-01-21 Ajinomoto Kk Verfahren zur Herstellung von Adenosin und 2',3'-O-Isopropylidenadenosin
JPS4944349B1 (enExample) * 1967-06-16 1974-11-27
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AT350735B (de) 1976-08-06 1979-06-11 Hoffmann La Roche Verfahren zur herstellung von neuen ribo- furanosyl-imidazolderivaten
AU529815B2 (en) * 1981-05-15 1983-06-23 Fisons Plc Optically active imidazole derivatives
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US4912092A (en) 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5118601A (en) * 1986-03-27 1992-06-02 The Regents Of The University Of California Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
US5008251A (en) * 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
FI875245A0 (fi) 1986-03-27 1987-11-27 Harry Edward Gruber Foerfarande foer oekande av utsoendringen av adenosin.
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5200525A (en) * 1989-01-24 1993-04-06 Gensia Pharmaceuticals Anti-seizure compounds
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
FI921092A7 (fi) * 1989-09-15 1992-03-13 Gensia Pharma Menetelmä neurodegeneratiivisten tilojen hoitamiseksi
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
IL99125A0 (en) * 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL99124A (en) * 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
JPH08504765A (ja) * 1992-12-16 1996-05-21 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖性の置換５−チアピリミジノンおよび５−セレノピリミジノン化合物
IL108524A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs
US5366960A (en) * 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5629298A (en) * 1995-03-13 1997-05-13 University Of Massachusetts Medical Center Adenosine as a positive inotrop in the compromised heart
US5645128A (en) * 1995-06-05 1997-07-08 Schwall; Charles F. Fire safety grease seal
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
WO2003037371A2 (en) 2001-10-31 2003-05-08 Universite Libre De Bruxelles Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
ES2192495B1 (es) * 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
AU2006230242B2 (en) 2005-03-28 2013-05-30 Pericor Therapeutics, Inc. Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
US20070082859A1 (en) 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
EP2247183A4 (en) 2008-01-25 2011-06-22 John E Foker METHOD AND COMPOSITIONS FOR INHIBITING PROGRESS FOR CHRONIC HEART FAILURE

Similar Documents

Publication Publication Date Title
JP2023088944A5 (enExample)
JP2015517489A5 (enExample)
JP2017528507A5 (enExample)
JP2016510326A5 (enExample)
JP2018534348A5 (enExample)
JP2016534153A5 (enExample)
JP2019515908A5 (enExample)
JP2014077003A5 (enExample)
WO2009033718A3 (en) Use of anti -inflammatory peptide 1 as a therapeutic agent
WO2009043458A3 (en) Use of oxytocin to treat many diseases
JP2013542247A5 (enExample)
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
WO2009039982A3 (en) Use of gip alone or in combination with dynorphin b as a therapeutic agent
WO2009033711A3 (en) Use of glp-1 as a therapeutic agent
WO2009033668A3 (en) Use of a peptide as a therapeutic agent
WO2009040068A3 (en) Use of a peptide as a therapeutic agent
FI3242666T3 (fi) Menetelmiä s1p1-reseptoriin liittyvien sairauksien hoitamiseksi
WO2009033783A3 (en) Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis
JP2014516942A5 (enExample)
JP2014515373A5 (enExample)
WO2009040029A3 (en) Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
WO2009033782A3 (en) Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
WO2009040028A3 (en) Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis
JP2014527040A5 (enExample)
WO2009033760A3 (en) Use of fibronectin fragment (196-203 ) as a therapeutic agent